Dengue severity by serotype in 19 years of pediatric clinical studies in Nicaragua

- Federico Narvaez^{1,2}, Carlos Montenegro², Jose Guillermo Juarez², Jose Victor Zambrana^{2,3}, Karla 3
- Gonzalez^{2,4}, Sonia Arguello², Fanny Barrios^{1,2}, Sergio Ojeda², Miguel Plazaola², Nery Sanchez², 4
- Daniel Camprubi^{5a}, Guillermina Kuan⁶, Gabriela Paz Bailey⁵, Eva Harris⁷, Angel Balmaseda^{2,4} 5
- ¹ Unidad de Infectología, Hospital Infantil Manuel de Jesús Rivera, Ministerio de Salud, 7
- 8 Managua, Nicaragua

1

2

6

18

- 9 ²Sustainable Sciences Institute, Managua, Nicaragua
- ³Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, 10
- 11 Michigan, USA
- 12 ⁴Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de
- 13 Salud, Managua, Nicaragua
- ⁵Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic 14
- 15 Infectious Diseases, San Juan, Puerto Rico
- ⁶Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua 16
- ⁷Division of Infectious Diseases and Vaccinology, University of California, Berkeley, Berkeley, CA 17
- 19 ^aCurrent affiliation: ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
- 20 Section: Vector-borne Diseases or Global Health and Neglected Tropical Diseases
- 22 Corresponding author: Angel Balmaseda, abalmaseda40@gmail.com

- 23 **Summary:** We analyzed dengue virus (DENV) disease severity stratified by serotype and immune
- status over 19 years of two pediatric studies in Nicaragua. DENV2 and DENV3 caused the most
- severity primarily secondary DENV2 cases and both primary and secondary DENV3 cases.
- 27 **Keywords:** dengue, serotype, disease severity, immune status, pediatric

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Abstract Background. Dengue virus, a major global health threat, consists of four serotypes (DENV1-4) that cause a range of clinical manifestations from mild to severe and potentially fatal disease. Methods. This study, based on 19 years of data from the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study in Managua, Nicaragua, investigates the influence of serotype and immune status on dengue severity. Study participants 6 months to 17 years old were followed during their hospital stay or as ambulatory patients, with dengue cases confirmed by molecular, serological, and/or virological methods. Results. We enrolled a total of 14071 participants, of whom 2954 (21%) were positive for DENV infection. Of 2425 cases with serotype result by RT-PCR, 541 corresponded to DENV1, 996 to DENV2, 718 to DENV3 and 170 to DENV4. Severe disease was more prevalent among secondary DENV2 and DENV4 cases, while similar disease severity was observed in both primary and secondary DENV1 and DENV3 cases. According to the 1997 World Health Organization (WHO) severity classification, both DENV2 and DENV3 had a higher proportion of severe disease compared to other serotypes, whereas DENV3 had the greatest percentage of severity under the WHO-2009 classification. DENV2 was associated with pleural effusion and low platelet count, while DENV3 correlated with both hypotensive and compensated shock. Conclusions. These findings emphasize the critical need for a dengue vaccine with balanced efficacy against all four serotypes, particularly as existing vaccines show variable efficacy by serotype and immune status, posing challenges for comprehensive protection, particularly in dengue-naïve individuals.

Introduction

The four serotypes of dengue virus (DENV1-4), a mosquito-borne *Flavivirus*, affect tens of millions of people worldwide [1]. In recent decades, dengue epidemics have consistently increased in tropical and subtropical regions of the world, with vector control as the principal means of prevention due to the lack of an effective, broadly used vaccine. Dengue viruses cause a range of clinical manifestations, from mild to severe and potentially fatal [2]. Understanding the contribution of serotype and immune status (primary versus secondary DENV infection) to clinical spectrum and severe disease is important for developing effective prevention and control strategies, particularly when introducing new vaccines with differential efficacy [3,4].

Developing a dengue vaccine has been challenging, primarily because it needs to provide protection against all four DENV serotypes, as imbalanced protection may result in antibody-dependent enhancement (ADE) of infection and disease [5,6]. The two approved dengue vaccines vary in efficacy by serotype and immune status. Specifically, Dengvaxia shows low efficacy for DENV2 and results in increased risk of hospitalization when administered to DENV-naïve recipients [7]; QDenga has no efficacy againt DENV3 in dengue-naïve children and unknown efficacy against DENV4 [8]. Importantly, both DENV2 and DENV3 have been associated with the greatest clinical severity [9–13]. Previous studies in our hospital cohort in Nicaragua also showed that DENV2 had a higher frequency of shock and internal hemorrhage when compared to DENV1 [14]. However, a comprehensive understanding of how dengue

severity varies by serotype and immune status remains limited, especially in Latin America

compared to other regions like Southeast Asia [10–13].

For the past 19 years, we have conducted studies on the diagnosis, classification, and clinical

management of dengue in Managua, Nicaragua [14-19]. This article describes the clinical

features and severe outcomes of dengue cases stratified by serotype and immune status in

almost 3000 patients presenting to our study health center or directly to our study hospital and

followed over the entire course of illness. Our results add to the clinical knowledge base of

dengue and can inform public health policies regarding implementation of novel vaccines for

disease control.

Methods

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Study design. We leverage two ongoing studies in Managua: the Pediatric Dengue Cohort

Study (PDCS; 2004 to present) and the Pediatric Dengue Hospital-based study (PDHS; 2005 to

present). The PDCS is the longest ongoing prospective dengue cohort study, currently in its 20th

year, following ~4,000 children aged 2-17 years old (y/o) in a community-based context, with

enhanced passive surveillance at the Health Center Sócrates Flores Vivas (HCSFV) in District 2 of

Managua [20]. To maintain the PDCS, 200-300 new 2-y/o children are enrolled every year,

along with an additional ~200 children 3-8 y/o to compensate for loss to follow-up [20]. The

PDHS is a clinical study that enrolls patients every year during the dengue season at the

Hospital Infantil Manuel de Jesus Rivera (HIMJR), Nicaragua's national pediatric reference

hospital. The PDHS enrolls children from 6 months to 14 y/o with symptoms and signs

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

suggestive of an arbovirus infection (WHO 1997) either in the emergency room or in the infectology unit of HIMJR [16] Children in the PDCS who require hospitalization are referred to the HIMJR, including patients 15-17 y/o. All participants were followed for their entire course of illness. Both the HCSFV and the HIMJR provide free health care services. Here, we present information from patients enrolled in both studies from September 2004 to February 2023. Classification of dengue disease severity. Dengue disease severity is defined by the World Health Organization (WHO) guidelines of 1997 (Dengue Fever [DF], Dengue Hemorrhagic Fever [DHF], Dengue Shock Syndrome [DSS]) [21] and 2009 (Dengue without Warning Signs [DwoWS], Dengue with Warning Signs [DwWS] and Severe Dengue [SD]) [2]. See Supplementary Table for more details. Here, we defined severe dengue disease as DHF/DSS (1997) or SD (2009). Laboratory methods and dengue diagnostics. Cell blood counts and blood chemistry tests were conducted using a Cell/Dyn Rubi (Abbot) and Biosystems BA 400 (Biosystems) automated system, respectively, and the trend over time in each patient's platelet and hematocrit values was reviewed. Dengue cases were confirmed by: 1) RT-PCR/viral isolation in acute samples and/or 2) seroconversion by DENV IgM MAC-ELISA and/or a seroconversion or ≥4-fold increase in total DENV antibody titers as measured by the Inhibition ELISA (iELISA) in paired acute and convalescent sera [22,23]. Viral RNA was initially detected using a nested RT-PCR and then using a multiplex Zika-Chikungunya-Dengue (ZCD) real-time RT-PCR [24-26]. DENV-positive samples were further analyzed to identify the infecting serotype using a multiplex DENV rRT-PCR [27]. Immune status was determined using iELISA in early convalescent samples; <2,560 was considered primary infection and >2,560 was considered secondary [15,22].

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

Statistical methods. Descriptive statistics were used to summarize demographic and dengue case data from the PDCS and PDHS, yielding participant counts, serotype distribution, and incidence data (see Supplementary Figures for a breakdown of all results by study). Incidence and distribution of infections by serotype and year were calculated. In addition, we analyzed severity by serotype using both the 1997 and 2009 WHO classifications, reporting the distribution of primary and secondary DENV infections and the severity classifications by each serotype in raw numbers and percentages. To analyze severity based on the 1997 and 2009 WHO dengue classifications by serotype and immune status, we used marginal effects from multivariate logistic regressions, producing predictive percentages of severe cases by serotype and immune status and applying an interaction term by serotype and immune status, controlling for age and sex. We implemented separate logistic regression models adjusting by immune status to calculate the odds ratios of each symptom and sign by serotype, using DENV1 as the reference value. The signs and symptoms comprised a range of clinical indicators such as hypotensive shock, poor capillary refill, pleural effusion, shock, hemoconcentration, low platelet counts, mucosal bleeding, ICU admission, inotropic drug usage, abdominal pain, vomiting, rash, headache, and myalgia. All analyses were performed in R version 4.2.2 (R core Team). All the analysis and figures were also stratified by study (PDCS and PDHS), these are shown in Supplementary Figures 1-8.

Ethics

The PDCS and PDHS are approved by the Institutional Review Boards of the Nicaraguan Ministry of Health (Protocol #CIRE-09/03/07-008.Ver24, CIRE-01/10/06-13.ver8) and the UC Berkeley Committee for the Protection of Human Subjects (Protocols 2010-09-2245, 2010-06-1649). Informed consent was obtained from all participants, parents, or legal guardians before enrollment; verbal assent was obtained from children 6-11 y/o and written assent from children ≥ 12 y/o.

Results

Demographic data and dengue cases. This study includes 14071 participants, of whom 2954 were positive for DENV infection. Yearly enrollment (PDHS) or community-based dengue cases (PDCS) varied depending on the epidemic season, with a maximum of 1751 children in 2019, a minimum of 37 children in 2004, and an average of 101 (standard deviation = 82) children per year combining both studies. Of the 2954 dengue cases, 2425 were DENV-positive by RT-PCR, with 541 DENV1, 996 DENV2, 718 DENV3, and 170 DENV4 (Table 1). Children were distributed almost evenly by sex, with 1207 (50%) females, and the average age of disease onset was 9 years in both studies (PDCS= 9.43 y/o, PDHS= 8.94 y/o) (Table 1). Children were followed throughout the course of disease and were managed as inpatients (mean hospitalization = 4.3 days) or outpatients (mean follow-up = 2.2 days) depending on disease severity. Of the 1132

PDCS DENV-positive participants, 397 (35%) required hospitalization and were transferred to the study hospital.

DENV serotype and immune status. Over the 19 years of the studies, we observed varying patterns of circulating DENV serotypes. DENV2 and DENV3 were the most common serotypes, with predominantly secondary infections for DENV2 and similar numbers of primary and secondary infections for DENV3 (Figure 1). Similar trends were observed in the PDCS and PDHS (Supplementary Figure 1). Interestingly, after 5 years of only DENV2 detection followed by 2 years of COVID-19 travel restrictions, in 2022, we detected epidemic levels of DENV4 for the first time and simultaneous circulation of all four serotypes. We observed 852 primary infections and 1573 secondary infections, with primary infections being most frequent in the ages of 6-10 years and secondary infections most prevalent in ages 11-17 years, with an almost equal distribution of sex (Table 2).

Dengue severity by immune status and serotype. The clinical spectrum caused by each serotype was analyzed based on 1997 and 2009 WHO definitions [2,21]. Using the 1997 classification, 1980 (80%) patients were DF and 411 (20%) were DHF/DSS (Table 3). Here, severity was defined as DHF/DSS. Using WHO-2009, 1403 (59%) patients were classified as DwWS and 408 (30%) with SD; therefore, severity was defined as SD (Table 3). Evaluating immune status, we observed that secondary cases were much more prevalent in severe disease caused by DENV2 infections (WHO-1997: 212 [92%] and WHO-2009: 110 [89%]) and DENV4 infections (WHO-1997: 4 [100%] and WHO-2009: 7 [100%]), while for DENV1 (WHO-1997: 26

[63%] secondary and WHO-2009: 48 [57%] secondary) and DENV3 (WHO-1997: 85 [61%] secondary and WHO-2009: 95 [49%] secondary), disease severity was observed in both primary and secondary infections (Table 3, Figure 2). Similar trends were observed in the PDCS and PDHS (Supplementary Figure 2). Thus, DENV3 was associated with the greatest severity in both primary and secondary infections according to both 1997 and 2009 WHO classifications, while DENV2 was most associated with DHF/DSS in secondary cases (see model-derived estimates compared to DENV1 in Figure 3 and Supplementary Figure 3).

Clinical signs and symptoms by serotype. Compared to DENV1, patients with DENV2 had greater odds of ICU admission (Odds Ration [OR] 2.71, 95% confidence interval [CI]: 1.43-5.62), hemoconcentration (OR=4.80, 2.06-14.04), low platelet count (OR=1.64,1.27-2.14 for <100,000 and OR=2.91, 1.92-4.56 for <50,000), pleural effusion (OR=2.84, 2.1.-3.88), and mucosal bleeding (OR=1.47, 1.01-2.18), the last only in secondary infections (Figure 4 and Supplementary Figure 4). We also observed a higher risk for rash (OR=1.87, 1.49-2.34) and fewer cases reporting headache (OR= 0.47, 0.37-0.59) and myalgia (OR=0.69, 0.54-0.88) compared to DENV1 (Figure 5). For DENV3, we observed an association with general symptoms such as rash (OR=3.11, 2.43-4.00) and myalgia (OR=1.58, 1.24-2.01) and alarm signs such as abdominal pain (OR=2.96, 2.28-3.87) and mucosal bleeding (OR=1.91, 1.42-2.58) (Figure 5). In terms of severity, DENV3 was correlated with pleural effusion (OR=2.54, 1.86-3.50), poor capillary refill (OR=2.06, 1.52-2.79), compensated shock (OR=2.30, 1.68-3.19), and hypotensive shock (OR=2.21, 1.46-3.42) (Figure 4). See Supplementary Figures 3-8 stratified by immune status and study.

Severe dengue cases, defined by the WHO-2009 criteria, were primarily characterized by shock. The WHO-2009 definition encompasses both compensated and hypotensive shock, unlike the WHO-1997 DSS definition, which includes only cases with hypotensive shock. Table 4 depicts patients identified upon admission with either compensated or hypotensive shock and those progressing from compensated to hypotensive shock, regardless of medical intervention. Notably, the severity of DENV1 is characterized by compensated shock, with only 12 (14%) of patients progressing from compensated to hypotensive shock, in contrast to DENV2 and DENV3, where more cases presented with hypotensive shock (30 [26%] and 24 [13%], respectively) or progressed from compensated to hypotensive shock (41 [35%] or 69 [37%], respectively). Further, other symptoms indicative of plasma leakage, such as pleural effusion and ascites, were higher in DENV2 (32% and 40%, respectively) and DENV3 (26% and 24%, respectively) compared to DENV1 (12% and 14%, respectively) (Figures 4 and 5 and Supplementary Figures 3-8 stratified by immune status and study). ICU admission was highest in DENV2 infections (11%) and lower in DENV1 (4%) and DENV3 (6%) cases. Laboratory abnormalities such as hemoconcentration and thrombocytopenia were more common in DENV2 (6% and 43%, respectively) and lower in DENV1 (1% and 25%) and DENV3 (1% and 29%).

Discussion

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

Dengue virus continues to expand globally, with multiple serotypes co-circulating that cause a wide range of clinical outcomes and can be potentially fatal. To evaluate how disease severity is modulated by immune status and DENV serotype, we leveraged two complementary long-

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

term studies in Nicaragua, including an integrated follow-up system from primary health center to hospital, based on 19 years of data. We used both the 1997 and 2009 WHO severity classification schemes, revealing important distinctions. Overall, we found that DENV2 and DENV3 caused the highest percent of DHF/DSS, and DENV3 caused the highest percent of SD, as well as the greatest number of severe clinical manifestations. This is consistent with previous publications [10-13,28,29] and of concern given that currently approved vaccines have poor efficacy against DENV2 for Dengvaxia and DENV3 for the Takeda vaccine in dengue-naïve recipients [7,8]. When analyzing immune status by serotype, we found that secondary cases predominated for DENV2 and DENV4, whereas more similar numbers of primary and secondary cases were observed for DENV1 and DENV3, supported by the literature [14,29-31]. Even in younger age groups, DENV2 and DENV4 showed a higher percentage of secondary cases, suggesting that primary cases infected by these serotypes were asymptomatic, consistent with previous reports [12,28,29,32]. Likewise, severe disease occurred much more often in secondary DENV2 and DENV4 cases, in contrast to DENV1 and DENV3 severe cases, which were more evenly distributed among primary and secondary cases, as reported elsewhere as well [13,28,30]. We analyzed the clinical spectrum of dengue considering the two distinct WHO severity classifications of 1997 and 2009. The 1997 definition is more focused on the pathophysiology of vascular leak leading to shock, while the 2009 definition aims for real-time identification of clinical disorders to enable timely management. The clinical spectrum of dengue using the

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

WHO-1997 definition revealed that most dengue cases evolved as DF, regardless of the serotype involved, with approximately 20% being classified as DHF/DSS. In contrast, using the 2009 classification, only 10% of cases evolved as DwoWS, with the majority as DwWS and 30% classified as SD. Approximately two-thirds of the patients classified as severe (DHF/DSS, WHO-1997) were classified as DwWS (WHO-2009). All exhibited a clinical picture characterized by plasma leakage and thrombocytopenia that did not progress to shock or respiratory distress. Other markers of severity such as plasma leakage that may not have progressed to shock and ICU admission were more common among DENV2 cases, underscoring the importance of this serotype. Breaking this down by serotype and immune status, secondary cases showed a higher proportion of WHO-1997 severe disease (DHF/DSS), especially in the case of DENV2 for DSS, while DENV3 had a high proportion of DHF/DSS in secondary cases as well as primary cases. Using the WHO-2009 classification, the serotype that exhibited the highest proportion of SD cases was DENV3 for both primary and secondary infections. However, overall, DENV2 was associated with severity using the 1997 classification, whereas DENV3 exhibited more severe cases according to both 1997 and 2009 definitions. It is important to note that the WHO-1997 DSS definition includes only cases with hypotensive shock, unlike the WHO-2009 SD definition, which encompasses both compensated and hypotensive shock. With respect to clinical signs and symptoms, severe thrombocytopenia (<50,000 platelets) was five times more prevalent in DENV2 than in DENV3 cases. On the other hand, of the WHO-2009

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

SD cases, two-thirds were not classified as severe by WHO-1997, because they failed to meet the full criteria for DHF/DSS. These were predominantly DENV3 cases (50%) followed by DENV1 and DENV2, almost entirely characterized by some form of shock without thrombocytopenia or hemorrhagic manifestations. Interestingly, most severe cases of DENV1 did not progress to hypotensive shock, maintaining only hemodynamic alterations such as poor capillary refill without advancing to hypotension and/or decreased pulse pressure. This is why DENV1 appears to be more severe than DENV2 when applying the 2009 classification. The severity of both DENV2 and DENV3 is characterized by signs of plasma leakage, resulting in ascites and pleural effusion. However, in comparison with DENV1, DENV3 is significantly associated with hemodynamic alterations leading to shock, either in its initial, compensated stage or during the hypotensive phase. Surprisingly, DENV2 did not have this association with shock, whether compensated or hypotensive, when compared to DENV1. This discrepancy may be attributed to a marked difference in the severity of DENV2 when analyzing immune status, where primary cases evolve favorably. Previous reports have also identified that DENV2 (WHO-1997) and DENV3 (WHO-1997 and WHO-2009) account for the greatest dengue severity [10,13,28,33]. One of our main strengths is the longitudinal nature of the study, with a single protocol in place for over almost two decades with consistency of clinical care and data collection. Another is the large number (almost 3000) of laboratory-confirmed pediatric dengue cases. Finally, we analyzed community-based and hospital-based cases, as well as those who progressed from the health center to the hospital - made possible by over a decade of careful work by our physicians harmonizing clinical variables between the two sites and a dedicated team of

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

programmers and data managers creating our customized informatics system and algorithm pipelines. One limitation of our study was the low circulation of DENV4, which prevented us from comprehensively analyzing the clinical signs and symptoms of severity in this serotype. Additionally, at the time of this analysis, one lineage of each serotype had circulated in Managua during the study period. We plan to expand this analysis following the introduction of new lineages of all the serotypes in 2022 (C. Cerpas, A. Balmaseda, in revision). Overall, our study reveals that DENV2 and DENV3 consistently lead to the highest severity in DENV2 primarily impacts secondary cases, while DENV3 induces severity regardless of immune status. These findings highlight the complex interplay between dengue serotypes, disease severity classifications, and immune status. Furthermore, our findings underscore the need for a vaccine that offers consistent efficacy against all four serotypes. Notes Authors contributions. FN, JGJ, GPB, EH, and AB contributed to the conceptualization of the study. FN, GK, and AB supervised the clinical studies. FN, FB, SO, MP, and NS conducted the studies. KG performed laboratory assays. CM and SA curated the data. JVZ, JGJ, DC and AB analyzed the data, JGJ, JVZ, DC, EH, and AB generated the initial figures and tables, FN, JGJ, EH, and AB wrote the initial manuscript draft, and DC and GPB edited the manuscript. All authors reviewed the manuscript for scientific content.

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

Acknowledgments. We are grateful to Cesar Narvaez for his contribution to data management for the Pediatric Dengue Hospital-based Study. We thank both past and current team members of the studies, based at the Hospital Infantil Manuel de Jesús Rivera, Sócrates Flores Vivas Health Center, the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y Referencia, and the Sustainable Sciences Institute in Nicaragua for their commitment and exceptional work. We are deeply grateful to the participants of the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study and their families. Financial support. This work was supported by the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) grant numbers PO1 Al106695 (EH) and RO1 Al099631 (AB). The studies were supported by PO1 Al106695 (EH), UO1 Al153416 (EH), U19 Al118610 (EH), R01 Al099631 (AB), U54 Al65359 (Barbour; subcontract AB), and BAA-NIAID-DAIT-NIHAI2009061 (Loeb; subcontract AB) from NIAID/NIH, and the Pediatric Dengue Vaccine Initiative grant VE-1 (EH) and the FIRST grant (EH) from the Bill and Melinda Gates Foundation. Potential conflicts of interest. The authors declare no conflicts of interest. Data and materials availability. After securing approval from the UC Berkeley Committee for the Protection of Human Subjects, individual data for figure reproduction can be shared with external researchers. For data arrangements, contact E.H. access please eharris@berkeley.edu or the CPHS at ophs@berkeley.edu. Standard data transfer agreements

govern all data used in this study. The associated code is available at the following link: https://github.com/jgjuarez/Narvaez_Dengue_Clinical_Severity.

Disclaimer. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention.

References

- 1. Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global variation in dengue transmission intensity. Sci Transl Med **2020**; 12:eaax4144.
- 343 2. WHO. Dengue guidelines for diagnosis, treatment, prevention and control

 ☐: new edition.
- **2009**.

- 345 3. de Silva A. Safety of Dengue Vaccine? Clin Infect Dis **2023**; 76:371–372.
- 346 4. Biswal S, Patel SS, Rauscher M. Safety of Dengue Vaccine? Clin Infect Dis **2022**; 76:771–772.
- 347 5. Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns.
- 348 Microbiol Spectrum **2014**; 2:10.1128/microbiolspec.aid-0022–2014.
- de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should
- We Be Concerned about Enhanced Disease after Vaccination? Cold Spring Harb Perspect
- 351 Biol **2018**; 10:a029371.
- 352 7. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine
- 353 Safety and Efficacy. N Engl J Med **2018**; 379:327–340.
- 8. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda's Dengue
- 355 Vaccine Candidate (TAK-003). Clin Infect Dis **2022**; 75:107–117.
- 356 9. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue Viremia Titer, Antibody Response
- Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis **2000**; 181:2–9.
- 358 10. Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of
- dengue hemorrhagic fever; an analysis of data collected in Bangkok, Thailand from 1994 to
- 360 2006. PLoS Negl Trop Dis **2010**; 4:e617.
- 361 11. Suppiah J, Ching S-M, Amin-Nordin S, et al. Clinical manifestations of dengue in relation to
- dengue serotype and genotype in Malaysia: A retrospective observational study. PLoS Negl
- 363 Trop Dis **2018**; 12:e0006817.
- 364 12. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic studies on Dengue in Santiago de
- 365 Cuba, 1997. Am J Epidemiol **2000**; 152:804.
- 366 13. Lovera D, Martínez-Cuellar C, Galeano F, Amarilla S, Vazquez C, Arbo A. Clinical
- manifestations of primary and secondary dengue in Paraguay and its relation to virus
- 368 serotype. J Infect Dev Ctries **2019**; 13:1127–1134.
- 369 14. Balmaseda A, Hammond S, Pérez L, et al. Serotype-specific differences in clinical
- manifestations of dengue. Am J Trop Med Hyg **2006**; 74:449–456.

- 371 15. Gutiérrez G, Gresh L, Pérez MÁ, et al. Evaluation of the Diagnostic Utility of the Traditional and Revised WHO Dengue Case Definitions. PLoS Negl Trop Dis **2013**; 7:e2385.
- 373 16. Narvaez F, Gutierrez G, Pérez MA, et al. Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity. PLoS Negl Trop Dis **2011**; 5:e1397.
- Hammond SN, Balmaseda A, Pérez L, et al. Differences in dengue severity in infants,
 children, and adults in a 3-year hospital-based study in NICARAGUA. Am J Trop Med Hyg
 2005; 73:1063–1070.
- 378 18. Rocha C, Silva S, Gordon A, et al. Improvement in hospital indicators after changes in dengue case management in Nicaragua. Am J Trop Med Hyg **2009**; 81:287–292.
- 380 19. Biswas HH, Ortega O, Gordon A, et al. Early Clinical Features of Dengue Virus Infection in Nicaraguan Children: A Longitudinal Analysis. PLoS Negl Trop Dis **2012**; 6:e1562.
- 382 20. Kuan G, Gordon A, Avilés W, et al. The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases. Am J Epidemiol **2009**; 170:120–129.
- 385 21. WHO, editor. Dengue haemorrhagic fever: diagnosis, treatment, prevention, and control. 2nd ed. Geneva: World Health Organization, 1997.
- 387 22. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science **2017**; 358:929–932.
- 389 23. Balmaseda A, Sandoval E, Pérez L, Gutiérrez CM, Harris E. Application of molecular typing techniques in the 1998 dengue epidemic in Nicaragua. Am J Trop Med Hyg **1999**; 61:893–391 897.
- Waggoner JJ, Ballesteros G, Gresh L, et al. Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya virus detection. J Clin Virol **2016**; 78:57–61.
- 394 25. Harris E, Roberts TG, Smith L, et al. Typing of Dengue Viruses in Clinical Specimens and Mosquitoes by Single-Tube Multiplex Reverse Transcriptase PCR. J Clin Microbiol **1998**; 36:2634–2639.
- 26. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol **1992**; 30:545–551.
- 400 27. Waggoner JJ, Abeynayake J, Sahoo MK, et al. Single-Reaction, Multiplex, Real-Time RT-PCR 401 for the Detection, Quantitation, and Serotyping of Dengue Viruses. PLoS Negl Trop Dis 402 **2013**: 7:e2116.

403 28. Soo K-M, Khalid B, Ching SM, Chee H-Y. Meta-Analysis of Dengue Severity during Infection 404 by Different Dengue Virus Serotypes in Primary and Secondary Infections. PLoS ONE **2016**; 405 11.

- 406 29. Balmaseda A, Standish K, Mercado JC, et al. Trends in Patterns of Dengue Transmission over 4 Years in a Pediatric Cohort Study in Nicaragua. J Infect Dis **2010**; 201:5–14.
- 408 30. Harris E, Videa E, Pérez L, et al. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg **2000**; 63:5–11.
- 410 31. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, et al. Sequential dengue virus infections 411 detected in active and passive surveillance programs in Thailand, 1994–2010. BMC Public 412 Health **2015**; 15:250.
- 413 32. Yung C-F, Lee K-S, Thein T-L, et al. Dengue Serotype-Specific Differences in Clinical
 414 Manifestation, Laboratory Parameters and Risk of Severe Disease in Adults, Singapore. Am
 415 J Trop Med Hyg 2015; 92:999–1005.
- 416 33. Guzmán MG, Kouri G, Valdes L, et al. Epidemiologic Studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol **2000**; 152:793–799.

Tables

419

420 421

422

423

Table 1. Study population: Demographic information, DENV serotype, and health facility,

PDCS and PDHS, Managua, Nicaragua, 2004-2023.

	Cohort HC* only	Hospital	Transferred from cohort HC to
	(n= 735)	(n= 1,284)	Hospital
			(n=397)
Age	9.43 (SD= 3.57)	8.94 (SD= 3.79)	10.48 (SD= 3.38)
< 1	0 (0%)	29 (2.3%)	0 (0%)
1-5	118 (16%)	232 (18%)	38 (9.6%)
6-10	333 (45%)	499 (39%)	144 (36%)
11-14	236 (32%)	520 (41%)	172 (43%)
15-17	59 (7.9%)	3 (0.2%)	42 (11%)
Sex			
Female	388 (51%)	619 (48%)	200 (50%)
Serotype			
DENV1	193 (26%)	266 (21%)	84 (21%)
DENV2	310 (42%)	540 (42%)	146 (37%)
DENV3	159 (21%)	445 (35%)	114 (29%)
DENV4	84 (11%)	32 (2.5%)	54 (14%)

424 *Health Center

Table 2. Age distribution of dengue cases by DENV serotype and immune status, PDCS and PDHS, Managua, Nicaragua, 2004-2023.

Serotypes	DENV1		DENV2		DI	ENV3	DENV4	
Age group	secondary		secondary		secondary			secondary
	primary		primary		primary		primary	
< 1	6 (2.1%)	0 (0%)	8 (4.7%)	1 (0.1%)	12 (3.2%)	2 (0.6%)	0 (0%)	0 (0%)
1-5	55 (20%)	11 (4.2%)	45 (26%)	93 (11%)	137 (37%)	39 (11%)	5 (18%)	3 (2.1%)
6-10	120 (43%)	99 (38%)	79 (46%)	301 (37%)	165 (45%)	165 (47%)	10 (36%)	37 (26%)
11-14	97 (34%)	135 (52%)	36 (21%)	393 (48%)	53 (14%)	129 (37%)	7 (25%)	78 (55%)
15-17	4 (1.4%)	14 (5.4%)	4 (2.3%)	36 (4.4%)	3 (0.8%)	13 (3.7%)	6 (21%)	24 (17%)
Sex								
F	135 (48%)	122 (47%)	89 (52%)	397 (48%)	187 (51%)	181 (52%)	19 (68%)	77 (54%)
М	147 (52%)	137 (53%)	83 (48%)	427 (52%)	183 (49%)	167 (48%)	9 (32%)	65 (46%)

Table 3. Dengue severity by serotype and immune status using the WHO 1997 and 2009 classifications, Pediatric Dengue Cohort Study and Hospital-based study, Managua, Nicaragua, 2004-2023.

Serotypes	DENV1		DENV2		D	ENV3	DENV4		
	secondary		lary secondary		secondary			secondary	
	primary		primary		primary		primary		
WHO-1997									
DF	256	228 (90%)	154	609 (74%)	315	260 (75%)	26	132 (97%)	
	(94%)		(92%)		(86%)		(100%)		
DHF	12	22 (8.7%)	12	167 (20%)	41	72 (21%)	0 (0%)	3 (2.2%)	
	(4.4%)		(7.1%)		(11%)				
DSS	3	4 (1.6%)	2	45 (5.5%)	12	15 (4.3%)	0 (0%)	1 (0.7%)	
	(1.1%)		(1.2%)		(3.3%)				
WHO-2009									
DWoWS	96	83 (33%)	70	108 (13%)	70	71 (20%)	14	68 (50%)	
	(35%)		(42%)		(19%)		(54%)		
DWWS	140	122 (48%)	84	603 (73%)	201	180 (52%)	12	61 (45%)	
	(52%)		(50%)		(55%)		(46%)		
SD	35	49 (19%)	15	110 (13%)	97	96 (28%)	0 (0%)	7 (5.1%)	
	(13%)		(8.3%)		(26%)				

Table 4. Compensated shock and hypotensive shock by DENV serotype.

Serotype	Only compensated shock	Only hypontensive shock	Hypotensive from compensated shock
DENV1	52 (62%)	20 (24%)	12 (14%)
DENV2	43 (38%)	30 (26%)	41 (35%)
DENV3	94 (50%)	24 (13%)	69 (37%)

440 441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

Figure Legends Figure 1. DENV circulation by immune status in the PDCS and PDHS combined, Managua, 2004-2022. Circulating serotypes and immune status in Managua are represented. The hospital study was not run in 2020 and 2021. Figure 2. Distribution by immune response among severe dengue cases, PDCS and PDHS combined, Managua, 2004-2022. Figure 3. Model derived severity by DENV serotype of infection and immune status in the PDCS and PDHS combined, Managua, 2004-2022. Model is adjusted by age and sex. Modelderived estimates compared to DENV1 stratified by WHO disease severity classification and immune status, as indicated. Due to sample size, DENV-4 was excluded from the analysis. Blue dotted line, DENV1 reference value. IR, immune response. Figure 4. Clinical signs, clinical lab results, and case management of dengue severity by serotype in both primary and secondary cases in the PDCS and PDHS combined, Managua, 2004-2022. Mucosal bleeding: epitaxis, gingivorrhagia, conjunctival bleeding, hematuria, hematemesis, melena, vaginal bleeding. ICU, intensive care unit. Figure 5. Symptoms of dengue by serotype in both primary and secondary cases in the PDCS and PDHS combined, Managua, 2004-2022.






Figure 2




Figure 3




Figure 4

Clinical variable	Serotype	Events	Observations	Percentage (%	·)		OR (95% CI)	p value
Hypotensive shock	DENV1	32	541	5.91		•		
	DENV2	71	996	7.13		-	1.16 (0.75 to 1.83)	
	DENV3	93	718	12.95		-	- 2.21 (1.46 to 3.42)	***
	DENV4	5	170	2.94	5	-	0.50 (0.17 to 1.21)	
Compensated shock	DENV1	64	541	11.83		•		
	DENV2	84	996	8.43			0.63 (0.44 to 0.90)	*
	DENV3	163	718	22.70		-	■— 2.30 (1.68 to 3.19)	***
	DENV4	1	170	0.59	←		0.04 (0.00 to 0.17)	**
Pleural effusion	DENV1	63	541	11.65		•		
	DENV2	319	996	32.03			2.84 (2.11 to 3.88)	***
	DENV3	185	718	25.77		-	=- 2.54 (1.86 to 3.50)	***
	DENV4	8	170	4.71	-	_	0.32 (0.14 to 0.64)	**
Ascitis	DENV1	47	345	13.62		•		
	DENV2	269	681	39.50			3.25 (2.29 to 4.70)	***
	DENV3	133	546	24.36		-	- 1.91 (1.32 to 2.79)	***
	DENV4	6	86	6.98	-	-	0.41 (0.15 to 0.94)	
Poor capillary refill	DENV1	80	502	15.94			es au our en Maria Comp e Tapard e Tablic (Me	
	DENV2	108	898	12.03		-	0.67 (0.48 to 0.93)	*
	DENV3	172	614	28.01		-	- 2.06 (1.52 to 2.79)	***
	DENV4	6	170	3.53	←■		0.18 (0.07 to 0.39)	***
Hemoconcentration	DENV1	5	541	0.92			(5.5.15.5.7)	
	DENV2	56	996	5.62			■→ 4.80 (2.06 to 14.04)	**
	DENV3	8	718	1.11			- 1.12 (0.37 to 3.74)	
	DENV4	1	170	0.59	-		- 0.56 (0.03 to 3.54)	
Platelets <100,000	DENV1	111	448	24.78			1.11 (0.00 10 0.04)	
	DENV2	421	989	42.57		-	1.64 (1.27 to 2.14)	***
	DENV3	199	685	29.05			1.25 (0.95 to 1.66)	
	DENV4	26	90	28.89			0.86 (0.51 to 1.43)	
Platelets <50,000	DENV1	27	448	6.03			0.00 (0.01 to 1.40)	
1 14161613 <30,000	DENV2	201	989	20.32		Ī	2.91 (1.92 to 4.56)	***
	DENV3	45	685	6.57			1.05 (0.64 to 1.74)	
	DENV4	45	90	4.44			0.54 (0.16 to 1.45)	
Mucosal bleeding	DENV4	78	541	14.42			0.54 (0.10 to 1.45)	
www.osai bieeuing			996	18.37			1 15 (0 05 to 1 55)	
	DENV2	183 179	718	24.93			1.15 (0.85 to 1.55)	***
	DENV3				_		- 1.91 (1.42 to 2.58)	***
ICU	DENV4	9	170	5.29		- 1	0.29 (0.13 to 0.57)	
100	DENV1		293	3.75		Ī	- 0.74 /4 40 to E.00\	**
	DENV2	66	585	11.28		_	2.71 (1.43 to 5.62)	
	DENV3	28	482	5.81	920		- 1.50 (0.75 to 3.22)	
	DENV4	1	79	1.27	←	1	0.30 (0.02 to 1.59)	
Inotropic drugs	DENV1	4	300	1.33		1		
	DENV2	14	647	2.16		-	1.36 (0.46 to 4.99)	
	DENV3	18	489	3.68		+	2.36 (0.86 to 8.29)	
					0.1 0	.4 1 :	2.7 7.4	
				Less like	ely than DE	ENV1 Mor	re likely than DENV1	

Figure 5

Clinical variable	Serotype	Events	Observations	Percentage (%)		OR (95% CI)	p value
Vomiting	DENV1	135	541	24.95	•		
	DENV2	254	996	25.50	+	0.99 (0.77 to 1.27)	
	DENV3	220	718	30.64	-	1.41 (1.09 to 1.82)	**
	DENV4	43	170	25.29	- -∔	0.90 (0.59 to 1.34)	
Abdominal pain	DENV1	104	538	19.33	÷		
	DENV2	259	993	26.08	-	1.30 (1.00 to 1.70)	
	DENV3	304	717	42.40	-	2.96 (2.28 to 3.87)	***
	DENV4	37	170	21.76	-	1.06 (0.68 to 1.62)	
Myalgia	DENV1	185	530	34.91	•		
	DENV2	270	992	27.22		0.69 (0.54 to 0.88)	**
	DENV3	295	692	42.63	-	1.58 (1.24 to 2.01)	***
	DENV4	69	169	40.83	<u>-</u>	1.08 (0.75 to 1.55)	
Headache	DENV1	378	529	71.46	÷		
	DENV2	529	989	53.49		0.47 (0.37 to 0.59)	***
	DENV3	480	693	69.26	+	1.02 (0.79 to 1.31)	
	DENV4	139	170	81.76	-	1.58 (1.02 to 2.48)	*
Rash	DENV1	292	541	53.97	•		
	DENV2	671	996	67.37	-	1.87 (1.49 to 2.34)	***
	DENV3	563	718	78.41	-	3.11 (2.43 to 4.00)	***
	DENV4	88	170	51.76	-	0.96 (0.67 to 1.37)	
				0.1	0.4 1 2.7	7.4	
				Less likely tha	an DENV1 More like	ely than DENV1	